Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zonisamide: physician and patient experiences.

Anthony Marmarou1, John M Pellock

  • 1International Epilepsy Consortium, Virginia Commonwealth University Medical Center, Old City Hall, 1001 E Broad Street, Suite 235, P.O. Box 980449, Richmond, VA 23298, USA. amarmaro@vcu.edu

Epilepsy Research
|May 5, 2005
PubMed
Summary

Zonisamide improved seizure control and quality of life in epilepsy patients, including those refractory to other antiepileptic drugs (AEDs). Physicians generally reported positive experiences and intended to continue zonisamide therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal sclerosis and temporal lobe epilepsy following febrile status epilepticus: The FEBSTAT study.

Epilepsia·2024
Same author

Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: The case for disease similarity.

Epilepsia·2017
Same author

Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation.

CNS drugs·2016
Same author

Risk factors for subsequent febrile seizures in the FEBSTAT study.

Epilepsia·2016
Same author

Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.

Epilepsy & behavior : E&B·2016
Same author

Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes.

Epilepsy & behavior : E&B·2016

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy affects millions globally, with many patients experiencing refractory seizures.
  • Antiepileptic drugs (AEDs) are a cornerstone of epilepsy management.
  • Zonisamide is an AED used to treat partial seizures.

Purpose of the Study:

  • To evaluate physician and patient experiences with zonisamide in an early access program.
  • To assess the efficacy and tolerability of zonisamide in a real-world epilepsy patient population.

Main Methods:

  • Physician and patient questionnaires were used to collect data on seizure history, AED use, seizure frequency, severity, and quality of life.
  • The Early Access and Support for Epilepsy (EASE) program provided zonisamide to patients.
  • Data were collected at initiation and after at least two months of zonisamide therapy.

Related Experiment Videos

Main Results:

  • Seizure control improved in 57.4% of patients, functional status in 37.1%, and other epilepsy symptoms in 30.6%.
  • Among patients with both initiation and follow-up data, seizure control improved in 53.6%, seizure severity in 58.8%, and quality of life in 62.1%.
  • Physicians intended to continue zonisamide therapy in 77.4% of patients, indicating positive treatment experiences.

Conclusions:

  • Zonisamide demonstrated positive outcomes in epilepsy patients, including those with refractory epilepsy.
  • Physician and patient experiences with zonisamide were generally favorable.
  • Zonisamide represents a viable treatment option for improving seizure control and quality of life in epilepsy management.